Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) has issued an update.
On May 12, 2026, Moleculin Biotech announced that an abstract presented at the European Hematology Association 2026 Congress reported a favorable cardiac safety profile for Annamycin, its next-generation anthracycline for relapsed or refractory acute myeloid leukemia. The pooled analysis covered 90 heavily pretreated patients across five clinical trials and focused on individuals with high cumulative prior anthracycline exposure.
An independent Cleveland Clinic cardio-oncology lab found no clinically significant treatment-related cardiotoxicity, with stable mean ejection fraction, no cases meeting criteria for left ventricular dysfunction and no link between cumulative dose and cardiac decline. Management indicated that these results support Annamycin’s potential to overcome the cardiac toxicity limits of traditional anthracyclines, strengthening its positioning as a differentiated option for heavily pretreated AML patients and potentially expanding its role in settings where anthracycline use is constrained by cardiotoxicity concerns.
The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, sustained losses, and continued cash burn with financing reliance). Offsetting factors include positive corporate developments around trial progress and strengthening IP, while technicals are neutral and valuation signals appear optically low but less reliable given the company’s pre-commercial fundamentals.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company developing therapies for hard-to-treat tumors and viruses. Its lead program, Annamycin (naxtarubicin), is a next-generation anthracycline designed to avoid multidrug resistance and reduce cardiotoxicity, and is being developed for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is also advancing the MIRACLE Phase 3 trial testing Annamycin with cytarabine in relapsed or refractory AML after a prior Phase 1B/2 study, and it is developing additional candidates such as WP1066 for brain, pancreatic and other cancers and WP1122 for certain viral and cancer indications.
Average Trading Volume: 174,846
Technical Sentiment Signal: Sell
Current Market Cap: $13.18M
See more data about MBRX stock on TipRanks’ Stock Analysis page.